Clinical Trial

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2023-10-06; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2024-01-26
Trial Details
NCT Number NCT06079398
Lead Sponsor Ascendis Pharma A/S
Conditions Achondroplasia
Enrollment 72 participants
Start Date 2024-01-23
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08